| Patient | Yul Brynner |
|---|---|
| Date of birth | 1963-07-11 |
| Identifiers | MRN HR-ML020-SYN; SSN (made up) 000-20-4572 |
| Document date | 2026-09-22 |
| Author | Simon Achterberg, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Tissue sequencing result and start of first-line pembrolizumab. [S]
Mr. Brynner returns one week later. The tissue sequencing report arrived yesterday: KRAS G12V and TP53 mutations, with no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration, in agreement with the plasma result. With the thoracic oncologist he chose pembrolizumab alone, given every 3 weeks, rather than with chemotherapy, because it is a preferred first-line option at his PD-L1 level and spares him the fatigue and nausea of chemotherapy while he works toward the stage. His first infusion is this afternoon. The dental examination four days ago found no problems. He is unchanged: weak voice, a little morning cough, no pain, and steady weight. The visit ran long with treatment teaching, and the symptom questionnaire was not completed. [S]
| Element | Detail |
|---|---|
| Tissue sequencing | KRAS G12V and TP53; no actionable alteration |
| Treatment decision | Pembrolizumab 200 mg every 3 weeks, first dose today |
| Dental status | Examination four days ago; no work needed |
| Symptoms | Unchanged; no pain |
| Tobacco | No tobacco |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Morning dry cough; no hemoptysis |
| Gastrointestinal | Negative | Bowels regular; no abdominal pain |
| Endocrine | Negative | No heat or cold intolerance, thirst, or dizziness |
| Integumentary | Negative | No rash or itching |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks | Every 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panel | Intravenous route | 2026-09-22 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-09-22 | Body height | 178 | cm | S |
| 2026-09-22 | Body weight | 71.8 | kg | S |
| 2026-09-22 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-09-22 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-09-22 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-09-22 | Heart rate | 78 | /min | S |
| 2026-09-22 | Respiratory rate | 16 | /min | S |
| 2026-09-22 | Body temperature | 36.6 | Cel | S |
| 2026-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-09-22 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-09-22 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-09-22 | Cortisol [Mass/volume] in Serum or Plasma | 14.2 | ug/dL | Morning (8 a.m.) reference interval | Normal | S |
| 2026-09-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-55 U/L | Normal | S |
| 2026-09-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 8-48 U/L | Normal | S |
| 2026-09-22 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 101 | U/L | 40-129 U/L | Normal | S |
| 2026-09-22 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-09-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-09-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 92 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-09-22 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-09-22 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-09-22 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-09-22 | Leukocytes [#/volume] in Blood by Automated count | 7.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-09-22 | Platelets [#/volume] in Blood by Automated count | 284 | 10*3/uL | 150-400 10*3/uL | Normal | S |
Vital signs recorded on 2026-09-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 71.8 kg |
| Voice | Breathy, low-volume voice |
| Lungs | Slightly reduced breath sounds at the left apex |
| Skin | No rash |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed | C34.12 | S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983. |
| Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer. |
| Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed | J38.01 | S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor. |
| Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed | R91.8 | S — Synthetic presenting imaging finding, recorded before the tissue diagnosis. |
| Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed | Z87.891 | S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Broad molecular profiling (tissue and plasma) | At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progression | Completed today | Tissue sequencing: KRAS G12V and TP53; no actionable alteration; concordant with plasma |
| Laboratory | Immune-related adverse event laboratory panel | Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated | Completed today | Baseline: TSH 2.1, free T4 1.2, morning cortisol 14.2, ALT 26, AST 23, alkaline phosphatase 101, bilirubin 0.6, glucose 94, all normal |
| Laboratory | Blood count, kidney function, and calcium before systemic therapy | Before each cycle | Completed today | Hemoglobin 13.6, white cells 7.6, platelets 284, creatinine 0.9 (eGFR 92), calcium 9.5 |
| Imaging | Response assessment imaging | Every 6 to 12 weeks on active systemic therapy | Due | First response CT about nine weeks after starting |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Morning dry cough; unchanged |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco |
| Survey | Distress and symptom screening (NCCN Distress Thermometer, ESAS) | Every visit; at minimum at key transitions | Deferred | Not done today, at the start of treatment, a key transition: the visit ran long with treatment teaching. Deviation from the every-visit and key-transition screen. No harm resulted: the palliative care team assessed his symptoms and distress in full a week later, and the next scores were lower. Corrective action: the ESAS and distress thermometer are now completed on a tablet at check-in, before the clinician sees him |
| Survey | Cancer-related fatigue screening | Every visit | Completed today | Tired by evening, unchanged; no daytime naps |
| Examination | Weight and dietary review | Each follow-up | Completed today | 71.8 kg, stable |
| Medication safety | Dental evaluation before a bone-modifying agent | Baseline, then periodically on zoledronic acid or denosumab | Completed today | Examination four days ago: no active disease, no extractions needed |
| Referral | Early integrated palliative care | Within eight weeks of diagnosis of advanced cancer | Referred | First visit next week |
| Self-management | Voice and work support | As needed | Referred | Injection medialization in two weeks; voice therapy started |
| Medication safety | Chemotherapy-induced peripheral neuropathy | Every visit during and after platinum or taxane | Not indicated | Pembrolizumab alone; no platinum or taxane |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026)
Follow-up: First pembrolizumab infusion this afternoon. Palliative care next week. Voice injection in two weeks. Cycle 2 in three weeks with the laboratory panel and the first zoledronic acid dose. Call the oncology line for any warning symptom. Next scheduled visit 2026-10-13: cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work. [S]